1/It is helpful to see a review of the concerns raised by professionals & patients prior to the publication of the 2016 CDC Opioid Prescribing Guideline - take a look. I will add highlights from my 2016 docket submission. Nearly all issues re-emerged in published research
2/ CDC’s Dose-related recommendations prioritized *relative* risk over *absolute* risk, and minimized consideration of interaction of risk and protective factors -
This is different from approaches applied to nearly all other risk evaluations in medicine (eg NSTEMI, A-fib)
3/The top-line recommendations lacked sufficient & explicit top-line recognition of the need to decide on care based on knowledge of overall patient life and functioning.
Note: DEA is investigating & prosecuting from the same narrow viewpoint
4/Urine drug testing and 3-day limits created brightline regulatory and legal targets (as indeed happened), but were tethered to modest data (the initial Rx duration actually IS associated with continued receipt, if one recognizes the limitations of that data)
5/The reason for concern at the time was the expectation, denied by the text of the Guideline itself, that the numeric thresholds would be given “regulatory force”.
Today, payers, Medicare, OIG and DEA agents use the Guideline that way. Reasons for hope ?
6/First the Guideline is being rewritten and the experts advising the CDC include members of the affected communities like @speakingabtpain , experts who have stuck their neck out for patients like @BethDarnall and others I deeply respect. They are clear cdc.gov/injury/pdfs/bs…
7/it is now accepted: with opioid Rx/capita at the level of 1992..
what sustains our crisis is *not what started it*
I wrote that line in late 2016 for “Turning the Tide or Riptide” - which became the most downloaded in the history of @SubstanceAbuseJ
🧵1/Our @uabmedicine Grand Rounds will feature a diagnostic showdown between Dr Martin Rodriguez and ChatGPT4
I am scared here because I don’t want AI to win
2/the case features behavioral changes, swearing, cognitive decline, cough, progressive weakness over 3 years.
I wonder about infectious and rheumatic disorders. Maybe primary neurological
Aspirations after a cognitive change is possible
Dr Rodriguez opens. Not much to go on.
3/ChatGPT generated a lot of text read by Dr Kraemer but it is pretty good, with emphasis on neurological disorders followed by a disclaimer “please note that this does not substitute for professional medical advice”. Both want more information
Truth💣 1/ The “NARXCare” opioid Rx risk algorithm is in all Prescription Monitoring Databases,ie ~1 bn Rx’s/year
NOW in @JournalGIM
✅evidence does not yet exist to support it as safe or protective
✅It has flourished due to lack of federal oversight link.springer.com/article/10.100…
2/The authors, led by Dr Michele Buonara, review the core argument as one in which this algorithm with low evidence to its favor
and high risk of harm
has gone unregulated
despite apparently fulfilling @US_FDA criteria that mandate it be regulated
3/Nearly all prescribers and national pharmacies now see the Bamboo Health, Inc proprietary “NARXcare” algorithm in a more prominent position *than the prescription history itself” when they view a prescription history.
1/Arguing for methadone deregulation, Dr. Ruth Potee notes that in an auditorium of 400 addiction specialists, almost NONE prescribe methadone (because they can't)
"Methadone is a miracle drug that no one has access to"
There are more people who offer Botox than offer methadone
Patient: “I can still do my activities”.
Doc: "No way, not really. I read the SPACE trial, and there is NO benefit (that would outweigh the opioids’ risk)”
"Shared decision-making" seems *doomed* here
1/I watch with concern as DEA prosecutions of MDs still seem to rely on “they prescribed more than I would” despite a 9-0 ruling of
Supreme Court last year
Sudden termination of opioids & progressive abandonment of 5-8 million patients is dangerous
1/Even on inpatient rounds, it is possible to introduce the idea that addiction isn’t (only) in the brain.
I contrast @NIAAAnews “brain disease” against a behavioral economics vide substance use as a pattern of behavior occurring in relation to environmental context
2/On teaching rounds we read aloud and discussed the @NIAAAnews brain-science model of addiction, pulling just a few lines off their website
3/then we read lines from Chapter 39 of “Evaluating the Brain Disease Model of Addiction” - this presents harmful substance use as a pattern of behavior based on assessment of competing rewards, delay or uncertainty of desired rewards, risks and costs - ie behavioral economics